AbbVie (ABBV) Issues Long-Term Outlook; Boosts Qtr. Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to AbbVie (ABBV) Issues Long-Term Outlook; Boosts Qtr. Dividend
November 2, 2015 9:58 AM EST
UBS reiterated a Buy rating and $78.00 price target on Abbvie (NYSE: ABBV) following the company's conference call. Management assumes no biosimiliars before 2022, and low mid-single digit annual price increases. On Humira biosimilar, management believes US biosimilars will likely infringe its dosing patents as they have to demonstrate efficacy at equal dosing.
Analyst... More
October 30, 2015 1:23 PM EDT
Cowen reiterated an Outperform rating and $77.00 price target on Abbvie (NYSE: ABBV) following the company's 3Q earnings results. Q3 EPS of $1.13 was $0.06 above consensus. Full year guidance has been raised to $4.26-4.28 (prior $4.10-4.30). Q3 sales of $5,944MM (+18%) were $54MM above... More
October 30, 2015 6:57 AM EDT
AbbVie (NYSE: ABBV) declared a quarterly dividend of $0.57 per share, or $2.28 annualized. This is an 11.8% increase from the prior dividend of $0.51.
The dividend will be payable on February 16, 2016, to stockholders of record on January 15, 2016, with an ex-dividend date of January 13,... More
